← Leaderboards
Suresh K Mittal
Purdue University West Lafayette
$9,510,410
Attributed
$9,510,410
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,510,410 · 4
By mechanism
R01$9,290,426 · 3
R29$219,984 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseAdenovirus VectorImmunityVectorVirusCessation Of LifePandemic DiseaseImmunizationInfluenzaFerretsVaccinesImmunogenicImmunogenicityCell Mediated Immune ResponseInfluenza A Virus, H9n2 SubtypeCattleAdenovirusesInfluenzavirusBasePandemic InfluenzaMouse ModelAntigensGenesInfluenza A Virus, H1n1 Subtype
Grant awards (23)
Novel delivery platform and antigen design for an effective COVID-19 vaccine$759,584
R01 · FY2025 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$467,130
R01 · FY2025 · AI · contact PI
Novel delivery platform and antigen design for an effective COVID-19 vaccine$764,234
R01 · FY2023 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$467,130
R01 · FY2023 · AI · contact PI
Novel delivery platform and antigen design for an effective COVID-19 vaccine$768,884
R01 · FY2022 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$459,430
R01 · FY2022 · AI · contact PI
Novel delivery platform and antigen design for an effective COVID-19 vaccine$773,534
R01 · FY2021 · AI · contact PI
Novel delivery platform and antigen design for an effective COVID-19 vaccine$792,476
R01 · FY2020 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$385,429
R01 · FY2018 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$385,429
R01 · FY2017 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$397,429
R01 · FY2016 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$396,429
R01 · FY2015 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$313,034
R01 · FY2009 · AI · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$313,263
R01 · FY2008 · AI · contact PI
Nonhuman adenoviral vectors for gene therapy$223,763
R01 · FY2008 · CA · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$316,296
R01 · FY2007 · AI · contact PI
Nonhuman adenoviral vectors for gene therapy$223,938
R01 · FY2007 · CA · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$329,302
R01 · FY2006 · AI · contact PI
Nonhuman adenoviral vectors for gene therapy$230,796
R01 · FY2006 · CA · contact PI
Adenoviral Vector-based Pandemic Influenza Vaccine$286,815
R01 · FY2005 · AI
Nonhuman adenoviral vectors for gene therapy$236,101
R01 · FY2005 · CA
NONHUMAN ADENOVIRUS VECTORS FOR GENE THERAPY$111,619
R29 · FY2001 · GM
NONHUMAN ADENOVIRUS VECTORS FOR GENE THERAPY$108,365
R29 · FY2000 · GM